RICHMOND, Va., Apr 8, 2003 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM) today announced that its Chairman and CEO, Geoffrey Allan, Ph.D., will be featured as part of CEOcast's Virtual Healthcare Conference, scheduled for April 9-23.
Dr. Allan's interview is currently scheduled to be available at approximately 3:30 pm ET on Thursday, April 10. During the interview, Dr. Allan is expected to discuss the driving factors behind the Company's recently reported stronger than expected first quarter guidance, updates on current clinical trials, potential for partnering with a major pharmaceutical company, and provide an update on the progress made in the recently announced named patient program as well as well as other matters relating to Insmed and its shareholders.
The interview will be available at http://www.ceocast.com. To access Dr. Allan's interview, click on the "Register Free" banner in the upper right corner of the page. You will be prompted to enter your name, e-mail address, and create a password. This will register you and send you back to CEOcast's home page. At that point, type in Insmed, its ticker symbol, "INSM," or click on the tab indicating "sector spotlight," and you will be directed to the interview.
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases with unmet medical needs. For further information about Insmed and rhIGF-I/rhIGFBP-3, please visit the company's corporate website at www.insmed.com.
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. Because of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
Baxter Phillips, III, 804/565-3041
Investor Relations International
Haris Tajyar, 818/981-5300